Summary of Two Human Clinicals on Flu Vaccinated and Nonvaccinated Subjects
Moyad et al., 2008, Moyad et al., 2010
Larry E. Robinson, Ph.D. and Stuart Reeves, Ph.D., ARCS, Scientific Affairs
Summary of Results:
Flu-Vaccinated Subjects Saw Significantly Reduced Symptoms from Upper Respiratory Tract infections (URTI): This study, published in a MEDLINE-indexed journal, was a randomized, double-blinded, placebo-controlled, 90-day trial on healthy subjects ages 18-65. The trial examined whether EpiCor had a beneficial effect on cold and flu symptoms on subjects who had received a flu vaccination. Results showed that EpiCor strengthens the immune system by significantly reducing cold and flu symptoms.
Non-Vaccinated Subjects Saw Significantly Reduced Symptoms from URTIs: This study, published in a MEDLINE-indexed journal, was a randomized, double-blinded, placebo-controlled, 90-day trial on healthy subjects ages 18-65. The trial examined whether EpiCor had a beneficial effect on cold and flu symptoms on subjects that did not receive a flu vaccination. Results mirrored the third trial showing EpiCor strengthens the immune system by significantly reducing cold and flu symptoms.
URTIs are reported to be the most commonly contracted illness. Maintaining a strong, balanced immune system is expected to reduce the average number of days with URTI symptoms. These two human clinicals examined whether EpiCor helped strengthen the immune system to reduce the incidence and duration of cold and flu symptoms for flu vaccinated and nonvaccinated subjects.
Both human clinicals used the same methodology and protocols and were during the same time frame and place. To determine the effect of EpiCor on strengthening the immune system, a 90-day trial was conducted in South Dakota during the worst expected cold and flu months – Jan. though Mar. Each study was a double-blinded, placebo-controlled trial on a group of 116 adults, ages 18-65, for a total of 232 subjects. One group had subjects that were vaccinated for the flu and the other had subjects that were not vaccinated.
At the beginning of the trials, subjects received physical examinations at screening to ensure a healthy study population and were randomly assigned to receive either EpiCor (500 mg) or placebo. Fasting blood samples were taken at randomization and at weeks six and twelve (when the trial ended). In addition, each subject was instructed to record the incidence, duration and severity of cold and flu symptoms.
In both studies, the EpiCor group had statistically significantly reduced (p<0.05) incidence of URTI symptoms compared to the placebo group. Additionally, when the EpiCor group had URTIs, the duration of symptoms was significantly shorter. The average number of days with symptoms was significantly reduced by 26% (Figure 3).
Figure 3. The Effect of EpiCor on the Number of Days with Symptoms Experienced by Vaccinated and Nonvaccinated Subjects
People who suffer from URTIs would benefit from having a strong, balanced immune system. These two studies show that EpiCor helps strengthen the immune system to reduce the incidence of URTI symptoms regardless of whether or not subjects were vaccinated for the flu.
Moyad, M.A., Robinson, L.E., Zawada, E.T., Kittelsrud, J.M., Chen, D.G., Reeves, S.G. and Weaver, S.E., (2008), Effects of a modified yeast supplement on cold/flu symptoms, Urologic Nursing, v. 28, p. 50-55
Moyad, M.A,, Robinson, L.E., Zawada, E.T., Kittelsrud, J.M., Chen, D.G., Reeves, S.G. and Weave, S.E., (2010), Immunogenic yeast-based fermentate for cold/flu-like symptoms in non-vaccinated individuals, Journal of Alternative and Complementary Medicine, v. 16, p.213-21.8